not tagged
pfizer
['crpc', ' 488p', 'sclc', 'pfizer']
at #esmo22, see results from part 1 and part 2a of a phase 1 study evaluating ezh2 inhibitor as monotherapy or in combination w/ an androgen receptor inhibitor + adt in patients with #follicularlymphoma, #sclc and #crpc 488p 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ